- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01381003
Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)
Phase I/II Gene Therapy Protocol for X-Linked Chronic Granulomatous Disease
Chronic Granulomatous Disease (CGD) is a rare inherited disorder in which patients suffer from severe infection and inflammation. The first indication of disease usually appears in early childhood. The basic defect found to be lie in specialised white blood cells called phagocytic cells, which are responsible for engulfing and destroying germs. In CGD, there is a defect in an enzyme (known as NADPH-oxidase) that is responsible for generating bleach like substances that are important for killing some important germs. In the form of the disease known as X-CGD (which accounts for two thirds of patients), there are defined mistakes in a gene called gp91-phox, which is a key part of the NADPH-oxidase.
In many cases, patients can be protected from infection by constant intake of antibiotics. However, in others potential life-threatening infections break through. In some cases patients also develop serious inflammation requiring high doses of drugs such as steroids. CGD can be cured by bone marrow transplant, but the best results are available when there is matched donor available. Transplant from unmatched donor have a much worse outcome.
Gene therapy of CGD can be performed by introducing a normal copy of human gp91-phox gene into the blood forming stem cells of patients' bone marrow by using a gene carrier (in this study called lentiviral vector). After treatment of the bone marrow cells in a specialised laboratory are given back to the patient and will grow into functional phagocytic cells.
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of at least one severe infection requiring hospitalisation despite standard antimicrobial prophylaxis and/or inflammation complications including one of the following: Oesophageal obstruction, gastric outlet obstruction, bladder outlet obstruction or colitis
- Molecular diagnosis confirmed by DNA sequencing and supported by laboratory evidence for absent or significantly reduced biochemical activities of the NADPH-oxidase
- Parental/Guardian and where appropriate Child's signed consent/assent
Exclusion Criteria:
- 10/10 HLA identical (A,B,C,DR,DQ) family or unrelated or cord blood donor unless there is deemed to be an unacceptable risk associated with an allogeneic procedure
- Contraindication for leukapheresis (anaemia Hb <8g/dl, cardiovascular instability, severe coagulopathy) or for administration of conditioning medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pCCLchimGp91s lentiviral vector transduced CD34+ cells
pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
|
pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival following gene therapy
Time Frame: 3 years follow up
|
3 years follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction in frequency of infections
Time Frame: evaluated from 1st year after treatment by clinical history, complete physical examination, haematological and microbiological tests
|
evaluated from 1st year after treatment by clinical history, complete physical examination, haematological and microbiological tests
|
Long term immune reconstitution
Time Frame: 3 years follow up
|
3 years follow up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adrian Thrasher, Professor, Great Ormond Street Hospital For Children NHS Foundation Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-MI-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Granulomatous Disease, Chronic, X-linked, Variant
-
University of California, Los AngelesNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's Hospital; California Institute for Regenerative Medicine (CIRM) and other collaboratorsRecruitingGranulomatous Disease, Chronic, X-linkedUnited States
-
IRCCS San RaffaeleFondazione TelethonRecruitingChronic Granulomatous Disease X-linked (X-CGD)Italy
-
National Institute of Allergy and Infectious Diseases...RecruitingChronic Granulomatous Disease (CGD) | X-Linked Chronic Granulomatous DiseaseUnited States
-
GenethonActive, not recruitingX-Linked Chronic Granulomatous DiseaseFrance
-
Hubert Serve, Prof., MDUnknown
-
GenethonActive, not recruitingX-Linked Chronic Granulomatous DiseaseUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingChronic Granulomatous Disease TransplantUnited States
-
Children's Hospital of Fudan UniversityRecruitingBCG | Vitamin D3 | Chronic-granulomatous DiseaseChina
-
National Institute of Allergy and Infectious Diseases...RecruitingChronic Granulomatous DiseaseUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedChronic Granulomatous DiseaseUnited States
Clinical Trials on pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion
-
Great Ormond Street Hospital for Children NHS Foundation...Recruiting
-
Great Ormond Street Hospital for Children NHS Foundation...RecruitingSevere Combined Immunodeficiency, X-LinkedUnited Kingdom
-
GenethonActive, not recruitingWiskott-Aldrich SyndromeUnited Kingdom, France
-
University of ManchesterUniversity College, London; Manchester University NHS Foundation Trust; Orchard... and other collaboratorsActive, not recruitingMucopolysaccharidosis Type IIIAUnited Kingdom
-
GenethonInstitute of Child Health; Great Ormond Street Hospital for Children NHS Foundation...Completed
-
GenethonHôpital Necker-Enfants MaladesCompleted
-
Dr. Melody Smith, MD, MSOrca Biosystems, Inc.Recruiting
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownX-linked Severe Combined ImmunodeficiencyUnited Kingdom
-
David WilliamsNational Heart, Lung, and Blood Institute (NHLBI); bluebird bio; California Institute... and other collaboratorsRecruitingA Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) (GRASP)Sickle Cell DiseaseUnited States
-
Donald B. Kohn, M.D.California Institute for Regenerative Medicine (CIRM)Recruiting